Serum osteoprotegerin and rankl levels in chronic alcoholic liver disease

被引:61
作者
García-Valdecasas-Campelo, E
González-Reimers, E
Santolaria-Fernández, F
De La Vega-Prieto, MJ
Milena-Abril, A
Sánchez-Pérez, MJ
Martínez-Riera, A
Gomez-Rodriguez, MD
机构
[1] Univ La Laguna Hosp, Med Interna Serv, Tenerife, Canary Islands, Spain
[2] Univ La Laguna Hosp, Lab Serv, Tenerife, Canary Islands, Spain
[3] Univ La Laguna Hosp, Nucl Med Serv, Tenerife, Canary Islands, Spain
来源
ALCOHOL AND ALCOHOLISM | 2006年 / 41卷 / 03期
关键词
D O I
10.1093/alcalc/agl004
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Objectives: Osteoprotegerin (OPG) is a decoy receptor that binds RANK-ligand (RANKL) and prevents osteoclast activation. Oestrogens, androgens, corticosteroids, parathyroid hormone (PTH), vitamin D, and several cytokines exert their effects on bone modulating the OPG/RANKL system. Since these substances become altered in chronic alcoholic liver disease, we investigated the OPG/RANKL system in alcoholic liver disease, its relation with bone mineral density (BMD) and with several hormones and cytokines. Methods: Serum OPG, RANKL, C-terminal cross-linking telopeptide of type 1 collagen, osteocalcin, insulin-like growth factor 1 (IGF-1), 1,25 dihydroxyvitamin D, IL-6, tumour necrosis factor (TNF)-alpha, PTH, estradiol, free testosterone and corticosterone were measured in 77 male alcoholic patients, 25 of them cirrhotics. All these patients underwent assessment of BMD at lumbar spine and left hip by a Hologic QDR-2000 (Waltham, MA) bone densitometer. Nineteen non-drinkers male sanitary workers of similar age served as controls. Results: Serum OPG levels were higher in patients (12.66 +/- 6.44 pmol/l) than in controls (6.59 +/- 1.58 pml/l, P < 0.005), especially in cirrhotics (15.97 +/- 7.03 pmol/l) vs non-cirrhotics (10.96 +/- 5.45 pmol/l, P < 0.001). Patients also showed higher telopeptide levels (0.60 +/- 0.36 vs 0.20 +/- 0.10 nmol/100 ml, P < 0.001), less IGF-1 [median = 192, interquartile range (IQR) = 46.7-175.99 ng/ml vs 150, IQR = 118.8-239.4 ng/ml, P < 0.001], vitamin D (25.5, IQR = 18.25-35 pg/ml vs 77.89, IQR = 57.48-98.53 pg/ml, P < 0.001) and osteocalcin (1.8, IQR = 1-3.6 ng/ml vs 6.04, IQR = 4.63-8.20 ng/ml, P < 0.001) than controls, but no differences in PTH and RANKL. Patients also showed lower Z-scores than controls at trochanter (-0.36 +/- 1.10 vs 0.26 +/- 0.87 in controls, P = 0.026), intertrochantereal area (-0.56 +/- 1.16 vs 0.46 +/- 1.01, P = 0.001), and total hip (-0.44 +/- 1.12 vs 0.42 +/- 1, P = 0.003). TNF-alpha levels were higher in patients (7.40, IQR = 4.30-17.80 pg/ml) than in controls (5.10, IQR = 4.40-8 pg/ml, P = 0.009), especially in cirrhotics (median = 13.90, IR = 6.10-21.10 pg/ml). OPG levels showed strong correlations with TNF-alpha (rho = 0.57, P < 0.001) and IL-6 (r = 0.62, P < 0.001), but not with BMD. Estradiol levels (31.83 +/- 13.11 pg/ml) were higher and free testosterone lower (13.62 +/- 11.96 pg/ml) in patients than in controls (20.36 +/- 3.08 and 18.19 +/- 4.68 pg/ml, respectively, P < 0.001 in both cases). Conclusion: OPG is raised in alcoholics, especially in cirrhotics, showing no relationship with decreased BMD. Also, raised TNF and IL-6 were observed, and were strongly, directly related with OPG levels. Since TNF and IL-6 enhance bone resorption, their relation with OPG suggests a protective effect of raised OPG on bone loss.
引用
收藏
页码:261 / 266
页数:6
相关论文
共 43 条
[1]   High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment [J].
Amato, G ;
Mazziotti, G ;
Sorvillo, F ;
Piscopo, M ;
Lalli, E ;
Biondi, B ;
Iorio, S ;
Molinari, A ;
Giustina, A ;
Carella, C .
BONE, 2004, 35 (03) :785-791
[2]   The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts [J].
Bord, S ;
Ireland, DC ;
Beavan, SR ;
Compston, JE .
BONE, 2003, 32 (02) :136-141
[3]   Osteoclast differentiation and activation [J].
Boyle, WJ ;
Simonet, WS ;
Lacey, DL .
NATURE, 2003, 423 (6937) :337-342
[4]   Expression and function of TNF-family proteins and receptors in human osteoblasts [J].
Bu, RF ;
Borysenko, CW ;
Li, YN ;
Cao, LH ;
Sabokbar, A ;
Blair, HC .
BONE, 2003, 33 (05) :760-770
[5]   Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice [J].
Dai, JL ;
Lin, DL ;
Zhang, J ;
Habib, P ;
Smith, P ;
Murtha, J ;
Fu, Z ;
Yao, Z ;
Qi, YH ;
Keller, ET .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (07) :887-895
[6]   ETHANOL REDUCES BONE-FORMATION AND MAY CAUSE OSTEOPOROSIS [J].
DIAMOND, T ;
STIEL, D ;
LUNZER, M ;
WILKINSON, M ;
POSEN, S .
AMERICAN JOURNAL OF MEDICINE, 1989, 86 (03) :282-288
[7]   Osteoprotegerin and RANKL in alcoholic liver cirrhosis [J].
Fábrega, E ;
Orive, A ;
García-Suarez, C ;
García-Unzueta, M ;
Antonio Amado, J ;
Pons-Romero, F .
LIVER INTERNATIONAL, 2005, 25 (02) :305-310
[8]   DIRECT EFFECTS OF ETHANOL ON BONE-RESORPTION AND FORMATION INVITRO [J].
FARLEY, JR ;
FITZSIMMONS, R ;
TAYLOR, AK ;
JORCH, UM ;
LAU, KHW .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1985, 238 (01) :305-314
[9]   DERANGED BONE-MINERAL METABOLISM IN CHRONIC-ALCOHOLISM [J].
FEITELBERG, S ;
EPSTEIN, S ;
ISMAIL, F ;
DAMANDA, C .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1987, 36 (04) :322-326
[10]  
Feuerherm AJ, 2001, SCAND J RHEUMATOL, V30, P229